Bevacizumab Is Expensive — But You Have More Options Than You Think

Let's start with the hard truth: Bevacizumab is one of the most expensive cancer drugs in widespread use. A single 400 mg vial of brand-name Avastin costs approximately $2,400 to $3,200 at wholesale. Depending on your weight, cancer type, and dosing schedule, your monthly treatment could run $5,000 to $15,000 or more before insurance.

If those numbers make your stomach drop, you're not alone. But here's the good news: most patients don't pay anything close to those full prices. Between insurance coverage, biosimilar savings, manufacturer programs, and patient assistance, there are real ways to bring your out-of-pocket costs down — sometimes to $0.

This guide walks you through every major option for saving money on Bevacizumab in 2026.

How Much Does Bevacizumab Cost Without Insurance?

Let's break down the numbers so you know what you're dealing with:

• Brand-name Avastin: Approximately $79.70 per 10 mg at WAC (wholesale acquisition cost), or about $3,188 per 400 mg vial
• Biosimilar Zirabev: Approximately $61.34 per 10 mg at WAC, or about $2,454 per 400 mg vial — roughly 23% less than Avastin
• Other biosimilars (Mvasi, Alymsys, Vegzelma, Avzivi, Jobevne): Similar pricing to Zirabev, typically 15-25% below brand Avastin

For a typical treatment course:

• A patient receiving 5 mg/kg every 2 weeks (for colorectal cancer) who weighs 70 kg would need 350 mg per dose — roughly one 400 mg vial, or about $5,000-$6,400 per month
• A patient receiving 15 mg/kg every 3 weeks (for lung cancer) who weighs 70 kg would need 1,050 mg per dose — about 2.5 vials, or approximately $6,000-$8,000 per treatment, which works out to roughly $8,000-$10,700 per month

These are cash prices. Most patients have insurance that covers a significant portion of these costs. But copays, coinsurance, and deductibles can still add up fast — especially with a cancer diagnosis.

Biosimilars: The First Way to Save

The simplest way to reduce your Bevacizumab costs is to ask about biosimilars. There are now six FDA-approved biosimilars of Avastin:

1. Mvasi (bevacizumab-awwb, Amgen)
2. Zirabev (bevacizumab-bvzr, Pfizer)
3. Alymsys (bevacizumab-maly, Amneal)
4. Vegzelma (bevacizumab-adcd, Celltrion)
5. Avzivi (bevacizumab-tnjn, Samsung Bioepis)
6. Jobevne (bevacizumab-nwgd, Sandoz)

Biosimilars are clinically equivalent to brand-name Avastin — same efficacy, same safety — but priced 15-25% lower. On a drug that costs thousands per treatment, that's meaningful savings. Your oncologist can prescribe a biosimilar, and in many cases, your infusion center may already be using one.

Learn more about how these products compare in our Bevacizumab overview guide.

Manufacturer Copay Assistance Programs

If you have commercial (private) insurance, the most impactful savings program is the Genentech Oncology Co-pay Assistance Program:

• What it covers: Out-of-pocket costs for Avastin (copays and coinsurance)
• How much you save: Eligible patients may pay as little as $0 per treatment
• How to enroll: Call (855) MY-COPAY (855-692-6729) or visit CopayAssistanceNow.com
• Who qualifies: Patients with commercial insurance taking Avastin for an FDA-approved indication. Not available for patients on government insurance (Medicare, Medicaid, Tricare, VA).

Some biosimilar manufacturers also offer copay assistance programs. Ask your oncologist's office or the biosimilar manufacturer directly about available programs for Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi, or Jobevne.

Patient Assistance Programs (For Uninsured or Underinsured Patients)

If you don't have insurance, or your insurance doesn't cover Bevacizumab adequately, patient assistance programs can provide the drug for free or at very low cost:

Genentech Patient Foundation

• What it offers: Free Avastin to eligible patients
• Who qualifies: Patients who are uninsured or underinsured and meet income criteria
• How to apply: Contact Avastin Access Solutions at Genentech. Your oncologist's office can help initiate the application
• Website: genentech-access.com

Independent Co-pay Foundations

Several independent nonprofit foundations help cancer patients with Bevacizumab costs:

• PAN Foundation: Provides financial assistance for out-of-pocket costs related to cancer treatment. Funds open and close periodically based on donations — apply early
• HealthWell Foundation: Offers copay and premium assistance for specific cancer diagnoses
• Patient Advocate Foundation: Co-pay relief and case management for cancer patients
• CancerCare: Financial assistance grants for treatment-related costs

These foundations typically cover both brand and biosimilar Bevacizumab and may be available to patients on Medicare or Medicaid who aren't eligible for manufacturer programs.

Other Ways to Save on Bevacizumab

Choose an In-Network Infusion Center

Bevacizumab is covered under the medical benefit (not pharmacy benefit) of most insurance plans, since it's administered by IV infusion. Your out-of-pocket costs depend on where you receive treatment:

• Hospital outpatient infusion centers may charge higher facility fees than freestanding centers
• Independent infusion centers or your oncologist's office may have lower total costs
• Always verify network status before scheduling at a new facility to avoid surprise bills

Understand Your Insurance Benefits

Key questions to ask your insurance company:

• Is Bevacizumab covered under my medical benefit?
• Is prior authorization required? (Almost always yes)
• What is my coinsurance percentage for infused drugs?
• Does my plan have an out-of-pocket maximum that would cap my annual costs?
• Are biosimilars covered at a different cost-sharing tier than brand Avastin?

Ask About Vial Optimization

Bevacizumab comes in 100 mg and 400 mg vials. Your dose is calculated based on body weight. Ask your provider whether vial rounding (slightly adjusting the dose to use full vials with no waste) is appropriate for your situation. This can reduce costs for your facility and potentially your copay.

Explore Medicare Part B Coverage

For Medicare patients, Bevacizumab is covered under Part B at ASP + 6%. You'll typically pay 20% coinsurance after meeting your Part B deductible ($240 in 2025). That 20% of a drug costing thousands per dose can still be significant — which is where the independent foundations listed above become crucial.

Medicare patients may also benefit from Medicare Supplement (Medigap) plans that cover Part B coinsurance, or Medicare Advantage plans with annual out-of-pocket caps.

Final Thoughts

Bevacizumab is a critical cancer treatment, and its cost shouldn't prevent you from getting the care you need. Between biosimilar options, the Genentech copay program (potentially $0 for commercially insured patients), the Genentech Patient Foundation (free drug for eligible uninsured patients), and independent foundations, most patients can find significant financial relief.

Start by talking to your oncologist's office about costs. Many practices have financial counselors or social workers who specialize in connecting patients with assistance programs. And use Medfinder to find Bevacizumab in stock at the most affordable location near you.

For more information about Bevacizumab, read our guides on what Bevacizumab is and how it works, side effects to watch for, and how to find it in stock near you.